Intravenouse immunoglobuline in dysautonomia.

Guillain-Barre Syndrome Humans Immunoglobulins, Intravenous Polyradiculoneuropathy, Chronic Inflammatory Demyelinating / chemically induced Primary Dysautonomias / drug therapy Quality of Life
Autoimmune autonomic gangliopathy (AAG) Chronic inflammatory demyelinating neuropathy (CIDP) Guillain-Barre syndrome (GBS) Intravenous immunoglobulins Neuropathy Small fiber neuropathy

Journal

Clinical immunology (Orlando, Fla.)
ISSN: 1521-7035
Titre abrégé: Clin Immunol
Pays: United States
ID NLM: 100883537

Informations de publication

Date de publication:
07 2022
Historique:
received: 03 12 2021
revised: 01 04 2022
accepted: 07 05 2022
pubmed: 16 5 2022
medline: 15 6 2022
entrez: 15 5 2022
Statut: ppublish

Résumé

Nowadays intravenous immunoglobulin (IVIg) treatment is considered to play a promising role in the autoimmune disease therapy. Despite its significant beneficial effects, the precise mechanism of action needs further studies, as well as recommended dosage in the treatment of autoimmune dysautonomia. In some diseases, like Guillain-Barre syndrome (GBS) and chronic inflammatory demyelinating neuropathy (CIDP), IVIg has a strong evidence that allows to recommend and prescribe the medication, while in other diseases only single case studies are available that requires further research. The review summarizes the currently available information on the effectiveness of IVIg in primary autoimmune neuropathies and neurological complications of systemic diseases, as well as side effects, features of clinical use with an emphasis on doses and treatment protocols in dysautonomia. Being safe and effective therapy, immunologic treatment is one of the most promising tools to achieve clinical remission of dysautonomia and good quality of life in autoimmune patients.

Identifiants

DOI: 10.1016/j.clim.2022.109039 PMID: 35569781
pubmed: 35569781
pii: S1521-6616(22)00120-6
doi: 10.1016/j.clim.2022.109039
pii:
doi:

Substances chimiques

Immunoglobulins, Intravenous 0

Types de publication

Journal Article Review Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

109039

Informations de copyright

Copyright © 2022 Elsevier Inc. All rights reserved.

Auteurs

N Gavrilova (N)

Ministry of Health of Russian Federation, Federal State Budgetary Institution "St. Petersburg Research Institute of Phthisiopulmonology", St. Petersburg 191036, Russia; Federal State Budget Educational Institution of Higher Education "St. Petersburg State University", University Emb., 7-9, Saint-Petersburg 199034, Russia.

E Kamaeva (E)

Federal State Budget Educational Institution of Higher Education "St. Petersburg State University", University Emb., 7-9, Saint-Petersburg 199034, Russia. Electronic address: kamaevaevelina@yandex.ru.

M Ignatova (M)

Federal State Budget Educational Institution of Higher Education "St. Petersburg State University", University Emb., 7-9, Saint-Petersburg 199034, Russia.

V Ryabkova (V)

Federal State Budget Educational Institution of Higher Education "St. Petersburg State University", University Emb., 7-9, Saint-Petersburg 199034, Russia; Pavlov First Saint Petersburg State Medical University, L'va Tolstogo str., 6-8, Saint Petersburg 197022, Russia.

M Lukashenko (M)

Federal State Budget Educational Institution of Higher Education "St. Petersburg State University", University Emb., 7-9, Saint-Petersburg 199034, Russia.

L Soprun (L)

Federal State Budget Educational Institution of Higher Education "St. Petersburg State University", University Emb., 7-9, Saint-Petersburg 199034, Russia.

L P Churilov (LP)

Ministry of Health of Russian Federation, Federal State Budgetary Institution "St. Petersburg Research Institute of Phthisiopulmonology", St. Petersburg 191036, Russia; Federal State Budget Educational Institution of Higher Education "St. Petersburg State University", University Emb., 7-9, Saint-Petersburg 199034, Russia.

Y Shoenfeld (Y)

Federal State Budget Educational Institution of Higher Education "St. Petersburg State University", University Emb., 7-9, Saint-Petersburg 199034, Russia; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; Zabludowicz Center for Autoimmune Diseases, Chaim Sheba Medical Center, 52621 Tel Ha Shomer, Israel; Ariel University, Ariel, Israel.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › États, signes et symptômes pathologiques › Processus pathologiques › Caractéristiques de la maladie › Maladie chronique › Troubles post-infectieux › Syndrome de Guillain-Barré › Intravenouse immunoglobuline in dysautonomia.
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Intravenouse immunoglobuline in dysautonomia.
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Globulines › Sérum-globulines › Immunoglobulines › Anticorps › Immunoglobulines par voie veineuse › Intravenouse immunoglobuline in dysautonomia.
questionsmedicales.fr › États, signes et symptômes pathologiques › Processus pathologiques › Caractéristiques de la maladie › Maladie chronique › Polyradiculonévrite inflammatoire démyélinisante chronique › Intravenouse immunoglobuline in dysautonomia.
questionsmedicales.fr › Maladies du système nerveux › Maladies du système nerveux autonome › Dysautonomies primitives › Intravenouse immunoglobuline in dysautonomia.
questionsmedicales.fr › Environnement et santé publique › Santé publique › Mesures épidémiologiques › Démographie › État de santé › Qualité de vie › Intravenouse immunoglobuline in dysautonomia.